Biological Safety Testing Market to Reach US$ 14.21 Billion by 2032 at 11.8% CAGR; North America Leads with 42% Share | Key Players Thermo Fisher Scientific, Charles River, Eurofins Scientific

The Biological Safety Testing market reached US$ 5.82 billion in 2024 and is expected to reach US$ 14.21 billion by 2032, growing at a CAGR of 11.8% during the forecast period 2025-2032. Market growth is driven by the increasing production of biologics, vaccines, cell and gene therapies, and biosimilars, along with stringent regulatory requirements to ensure product safety, purity, and quality before commercialization.

Biological safety testing plays a critical role in detecting contaminants such as viruses, mycoplasma, endotoxins, and residual DNA in biologic products. The market is high in North America, supported by a strong biopharmaceutical manufacturing base, advanced regulatory frameworks, and high R&D spending. Europe follows with steady demand due to strict quality standards, while Asia-Pacific is emerging as a high-growth region driven by expanding biopharma manufacturing, increasing outsourcing of testing services, and rising investments in life sciences infrastructure.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/biological-safety-testing-market?sai-v

The biological safety testing market refers to the global industry focused on testing services and technologies used to ensure the safety, purity, and quality of biologics, pharmaceuticals, and medical products.

Key Developments
✅ January 2026: In North America, adoption of automated biological safety testing platforms increased across pharmaceutical, biotech, and medical device sectors to accelerate safety profiling and regulatory compliance, with leading technologies from Thermo Fisher Scientific, PerkinElmer, and Agilent Technologies enabling high-throughput cytotoxicity and genotoxicity assays.

✅ January 2026: In Europe, harmonization of regulatory requirements by authorities (including updated ISO and EMA guidelines) drove demand for integrated bioassay and molecular diagnostic safety testing workflows, supported by solutions from bioMérieux, Roche Diagnostics, and QIAGEN that enhance pathogen detection and endotoxin assessment.

✅ December 2025: In Asia-Pacific, expansion of contract testing and CRO networks accelerated uptake of cell-based and immunotoxicity testing services, with service expansion by SGS, Intertek, and Eurofins Scientific improving access to GLP-compliant biological safety testing for local and regional developers.

✅ December 2025: Globally, advancements in next-generation sequencing (NGS)-enabled safety assays and high-content screening enhanced detection of adventitious agents and biological contaminants, with innovation from Illumina, PerkinElmer, and Luminex Corporation advancing assay sensitivity and throughput.

✅ November 2025: In Latin America, increased regulatory emphasis on biologics, vaccines, and advanced therapeutic product safety supported expanded use of microbial and sterility testing services, delivered by providers such as Eurofins Scientific, Charles River Laboratories, and Toxikon Corporation.

✅ October 2025: Worldwide, integration of AI and machine learning analytics into biological safety testing platforms improved predictive toxicology and data interpretation, with contributions from ExxonMobil Data Analytics (life sciences division), Certara, and Dotmatics enhancing data quality and risk assessment.

Mergers & Acquisitions
✅ January 2026: In the United States, Thermo Fisher Scientific acquired a biological safety testing automation technology company to expand its integrated safety testing solutions and strengthen laboratory workflow offerings.

✅ December 2025: In Europe, bioMérieux completed the acquisition of a molecular safety assay developer to broaden its pathogen detection and biological safety testing portfolio.

✅ November 2025: In Asia-Pacific, Eurofins Scientific acquired a regional contract biological testing and safety services provider to enhance its GLP testing network and service capabilities.

Key Players
Avance Biosciences | Cytovance Biologics | Eurofins Scientific | Lonza | Merck KGaA | Promega Corporation | Thermo Fisher Scientific | Toxikon | WuXi AppTec | Charles River Laboratories | Others

Key Highlights
Thermo Fisher Scientific holds 22% share, driven by its broad portfolio of laboratory services, strong global infrastructure, and deep integration across biopharma research, development, and manufacturing workflows.

Charles River Laboratories holds 18% share, supported by its leadership in preclinical research services, toxicology testing, and long-term partnerships with pharmaceutical and biotechnology companies.

Eurofins Scientific holds 15% share, leveraging its extensive global laboratory network, strong expertise in bioanalytical and safety testing, and diversified life sciences service offerings.

Lonza holds 14% share, driven by its strong position in biologics development and manufacturing, advanced cell and gene therapy capabilities, and end-to-end CDMO services.

WuXi AppTec holds 12% share, supported by its integrated discovery, development, and manufacturing platforms and strong client base across global biopharma companies.

Merck KGaA holds 8% share, leveraging its life science tools, reagents, and process solutions widely used in biopharmaceutical research and quality testing.

Promega Corporation holds 5% share, driven by its specialized biochemical assays, reagents, and tools supporting drug discovery and toxicology research.

Toxikon holds 3% share, focusing on GLP-compliant toxicology testing and safety assessment services for medical devices and pharmaceuticals.

Avance Biosciences holds 2% share, contributing through niche bioanalytical and in vivo testing services for early-stage drug development.

Cytovance Biologics holds 1% share, focusing on biologics development, microbial fermentation, and protein expression services.

Others hold 0-5% share, comprising regional CROs and emerging life science service providers expanding specialized testing and biopharmaceutical support capabilities.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=biological-safety-testing-market?sai-v

(Single User Report: USD 4350 & One Year Database Subscription: USD 12K)

Market Drivers
- Increasing regulatory requirements and stringent safety standards for biologics, vaccines, and therapeutic proteins driving demand for biological safety testing.

- Rising global biopharmaceutical R&D and manufacturing activities necessitating comprehensive safety evaluation throughout development and commercialization.

- Growing emphasis on patient safety and risk mitigation leading to mandatory testing for contaminants, adventitious agents, and impurities.

- Advancements in molecular and analytical technologies enhancing sensitivity, - speed, and accuracy of biological safety assays.

- Expansion of contract testing and CDMO services enabling scalable safety testing support for biotech and pharmaceutical developers.

Industry Developments
- Adoption of next-generation sequencing (NGS), PCR, and high-throughput screening platforms for rapid detection of pathogens and contaminants.

- Integration of automated and digital testing workflows to improve laboratory efficiency, reproducibility, and data integrity.

- Strategic partnerships between biopharma companies, CROs, and safety testing service providers to expand global testing capacity.

- Growing implementation of in-silico safety assessment tools and AI-driven analytics to complement traditional biological assays.

- Development of specialized assays and kits for emerging biologics, cell and gene therapies, and viral vector products.

Regional Insights
North America - 42% share: "Driven by strong biopharmaceutical R&D ecosystem, stringent regulatory oversight, high adoption of advanced testing technologies, and extensive safety compliance requirements."

Europe - 28% share: "Supported by robust pharma and biotech sectors, harmonized regulatory frameworks, and widespread use of cutting-edge safety testing platforms."

Asia Pacific - 22% share: "Fueled by expanding biologics manufacturing, increasing clinical trial activity, rising healthcare investments, and growing regulatory alignment."

Latin America - 5% share: "Driven by improving biopharma infrastructure, increasing contract testing demand, and expanding biotech activities."

Middle East & Africa - 3% share: "Supported by emerging biotechnology initiatives, growing healthcare investments, and increasing focus on biologics safety compliance."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/biological-safety-testing-market?sai-v

Key Segments

By Product
Reagents and kits dominate the market due to their recurring use in routine testing and quality control processes. Instruments account for a significant share, supported by increasing automation and demand for high-throughput and reliable testing systems. Other products include consumables and accessories that support laboratory operations and compliance requirements.

By Application
Vaccines and therapeutics represent a major application segment, driven by stringent regulatory requirements for safety and quality assurance. Cellular and gene therapy is a fast-growing segment, supported by rising development of advanced therapies and the need for rigorous biological safety testing. Blood and blood-based therapy hold a substantial share due to continuous demand for sterility and endotoxin testing. Other applications include medical devices, tissue engineering, and biopharmaceutical research.

By Test
Sterility tests account for the largest share, driven by mandatory regulatory standards across biopharmaceutical manufacturing. Endotoxin tests are widely adopted to ensure product safety and prevent pyrogenic reactions. Bioburden tests play a critical role in monitoring microbial load during manufacturing processes. Other tests include mycoplasma testing and environmental monitoring, supporting comprehensive biological safety assurance.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.